Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
29 hedge funds and large institutions have $29.5M invested in Trillium Therapeutics Inc. in 2016 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 6 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
0% more funds holding
Funds holding: 29 → 29 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
40% less capital invested
Capital invested by funds: $48.9M → $29.5M (-$19.4M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.25M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.19M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$413K |
| 4 |
Millennium Management
New York
|
+$194K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$121K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$3.8M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$1.68M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$342K |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$211K |
| 5 |
Bank of New York Mellon
New York
|
-$138K |
TRIL Hedge Fund Activity: Q1 2016 in Review
29 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q1 2016, worth a combined $29.5M — down 40% from $48.9M a quarter earlier.
Fund positioning in TRIL was balanced in Q1 2016: 6 funds opened new positions, 6 closed out, 8 added to existing stakes and 5 trimmed.
The largest buyer was Oxford Asset Management, opening a new position worth an estimated $1.25M. The largest seller was Private Capital Advisors, cutting an estimated $3.8M.
- 29 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $29.5M of Trillium Therapeutics Inc. stock for Q1 2016, down 40% quarter-over-quarter.
- 6 funds opened new Trillium Therapeutics Inc. positions in Q1 2016 and 6 closed out, a net change of 0 holders.
- The largest Trillium Therapeutics Inc. buyer in Q1 2016 was Oxford Asset Management, an estimated $1.25M added.
- The largest Trillium Therapeutics Inc. seller in Q1 2016 was Private Capital Advisors, an estimated $3.8M sold.
Based on aggregated 13F filings for Q1 2016.